Understanding your CBC (complete blood count) is one of the most helpful things you can do as an MPN patient. Your CBC is how you and your hematologist track polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF), and how you both know whether treatment is working. Lab reports aren’t written for patients, and with […]
Polycythemia Vera Hematocrit: Is Below 45% Enough?
By David Wallace – Patient perspective | September 25, 2026 The established polycythemia vera hematocrit target is below 45%. That goal lowers the risk of serious blood clots and cardiovascular death. It does not necessarily mean symptom relief. I learned that the hard way. My circulation-related symptoms often started around 42%, well before I hit the […]
Mimrylo Earns NCCN Category 1 Recommendation for PV
By David Wallace – September 23, 2026 Mimrylo (rusfertide) has been added as a Category 1 treatment option for both low- and high-risk polycythemia vera (PV) in the National Comprehensive Cancer Network’s updated guidelines. For patients who need frequent phlebotomies, the update is another reason to ask whether a medicine designed to control hematocrit could […]
How I Achieved Complete Molecular Remission From Polycythemia Vera (PV)
by David Wallace, Founder, PV Reporter & MPN Cancer Connection When I was first diagnosed with polycythemia vera, nobody told me that PV remission was even possible. And the only treatment I was given, phlebotomy alone, guaranteed it wouldn’t be. Today, my blood counts are normal, and the molecular markers driving my PV are undetectable. […]




